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192Objective: Rotary type left ventricular assist devices have mitigated the problem of durability associated with
earlier pulsatile pumps and demonstrated improved survival. However, the compromise is the loss of pulsatility
due to continuous flow and retained percutaneous driveline leading to increasedmortality andmorbidity. Lack of
pulsatility is implicated in increased gastrointestinal bleeding, aortic incompetence, and diastolic hypertension.
We present a novel, wirelessly powered, ultra-compact, implantable physiologic controller capable of running a
left ventricular assist device in a pulsatile mode with wireless power delivery.
Methods: The schematic of our system was laid out on a circuit board to wirelessly receive power and run a left
ventricular assist device with required safety and backup measures. We have embedded an antenna and wireless
network for telemetry. Multiple signal processing steps and controlling algorithm were incorporated.
The controller was tested in in vitro and in vivo experiments.
Results: The controller drove left ventricular assist devices continuously for 2 weeks in an in vitro setup
and in vivo without any failure. Our controller is more power efficient than the current Food and Drug
Administration–approved left ventricular assist device controllers. When used with electrocardiography
synchronization, the controller allowed on-demand customization of operation with instantaneous flow and
revolutions per minute changes, resulting in a pulsatile flow with adjustable pulse pressure.
Conclusions: Our test results prove the system to be remarkably safe, accurate, and efficient. The unique
combination of wireless powering and small footprint makes this system an ideal totally implantable physiologic
left ventricular assist device system. (J Thorac Cardiovasc Surg 2014;147:192-202)By 2030, it is anticipated that 10 million people in the
United States will live with heart failure (1/33 people).1,2
However, the available donor hearts remain stagnant at
approximately 2000 per year.3 In recent years, implantable
left ventricular assist devices (LVADs) have offered another
option to this ill population. Although showing a survival
advantage, the earlier pneumatically driven positive
displacement pumps showed high mechanical failure due
to wear and tear associated with multiple moving parts
and associated friction. The technologic improvement of
rotary pumps with a single moving part has led to increased
durability and patient survival compared with their earlier
generations both as a bridge to transplant and as destination
therapy. However, the improved durability of rotary blood
pumps comes at the compromise of having a pulseless
continuous blood flow.e Bonde Artificial Heart Laboratory, Department of Surgery, Yale School of
cine, New Haven, Conn.
res: The authors own the patent on this device in conjunction with
University.
the 93rd Annual Meeting of The American Association for Thoracic
ry, Minneapolis, Minnesota, May 4-8, 2013.
d for publication May 9, 2013; revisions received Aug 20, 2013; accepted for
ation Sept 4, 2013; available ahead of print Oct 31, 2013.
for reprints: Pramod Bonde, MD, Center for Advanced Heart Failure and
plantation, Section of Cardiac Surgery, 330 Cedar St, 204 Boardman,
Haven, CT 06520 (E-mail: pramod.bonde@yale.edu).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.09.012
The Journal of Thoracic and Cardiovascular SurgDespite the technologic advances to the pump body, the
requirement of a transcutaneous driveline to conduct power
(previously needed for shuttling air for pulsatile devices),
controller algorithms, and data exchange between the
pump and the extracorporeal controller remains unchanged.
Despite the benefits of this technology, driveline-associated
infections are a common and devastating complication4,5
that causes a significant negative impact on a patient’s
quality of life and increased medical cost.6 The presence
of nonphysiologic pulseless blood flow in patients
with long-term LVAD support has been implicated in
increased gastrointestinal bleeding,7-9 limited cardiac
unloading,10,11 vascular malformations,12,13 and aortic
incompetence.14,15 Moreover, because successful LVAD
explantation occurs less often with continuous-flow pumps,
concerns have been raised regarding their use in patients
with a potential for myocardial recovery.
We have previously demonstrated the efficacy of a
Free-Range Resonant Electrical Energy Delivery (FREE-D)
system that uses high-quality factor resonant coupling tech-
nology to wirelessly transfer energy to power an LVAD.16
The FREE-D system uses magnetically coupled resonators
to seamlessly supply energy without compromising mobility
or requiring direct contact between the patient and the energy
source,17 thus freeing the patient from a driveline. Applica-
tion of such technology also requires a small implantable
controller with wireless communication.ery c January 2014
Abbreviations and Acronyms
ECG ¼ electrocardiography
EMF ¼ electromotive force
FREE-D ¼ Free-Range Resonant Electrical
Energy Delivery
LVAD ¼ left ventricular assist device
MCL ¼ mock circulation loop
rpm ¼ revolutions per minute
DRPM ¼ difference between systolic and
diastolic pump speeds
UMC-Physio ¼ ultra-compact implantable
physiologic controller
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DIn the current study, we present an ultra-compact implant-
able physiologic controller (UMC-Physio) to entirely un-
tether patients from the LVAD driveline, increase patients’
quality of life, and significantly reduce complications associ-
ated with nonphysiologic continuous flow.MATERIALS AND METHODS
Left Ventricular Assist Device Motor
Current-generation LVADs are based on brushless direct current motors,
also known as electronically commutated motors that are powered by a
direct current electric source (Appendix 1). An LVAD has 3 sets of coils
positioned around its impeller. Once a coil is energized, it produces a
magnetic field that causes the permanent magnet on the rotor to align
with that magnetic field, which in turn rotates the impeller. However, the
rotating action stops when the rotor is aligned with the magnetic field
created by the energized coil. To keep the impeller in motion, the coils
are energized in a particular sequence (120 out-of-phase from one
another). The process of activating and deactivating the coils to keep the
impeller spinning is termed ‘‘commutating.’’
Pump Speed
Because an LVAD does not have any sensor, the speed of the pump is
measured from back electromotive force (EMF) generated by the motor’s
rotation. The amplitude of the back EMF is proportional to the angular
velocity of the LVAD, but its shape will not change with speed and only
depends on the pump characteristic. Our controller uses attenuation and
filtering processing to sense this signal. The attenuation is required to bring
the signal down to an allowable commonmode range of the sensing circuit,
and the low pass filtering is necessary for smoothing the high switching
frequency noise.
When to Commutate and Power Efficiency
The challenge in controlling a brushless direct current motor is
knowing when to commutate, because commutation must occur at pre-
cise points during rotation for the motor to have maximum torque and
smooth operation. Because the implanted system must comply with
the highest efficiency, we have incorporated a control algorithm that
spins the motor more efficiently to reduce the overall power consump-
tion by calculating when to commutate on the basis of the back EMF
of the motor. To further reduce the power, we have introduced a sleep
mode for our system that wakes the controller up at only certain point
for a short amount of time (5 ms/s) to capture the sensor data and
monitor the device operation.The Journal of Thoracic and CaMode of Operation (Mimicking Physiologic Flow)
The purpose of an LVAD physiologic controller is to match the aortic
pressure to a certain value derived from the patient activity. The
UMC-Physio has 2 different modes of operation to mimic physiologic
flow: continuous and pulsatile modes. In the continuous-flow mode, the
user can set 1 speed. However, for the pulsatile mode, the user is required
to define separate speeds during systole and diastole. Moreover, in case of a
patient with potential myocardial recovery, the controller will have a higher
speed during diastole and a lower speed during systole to decrease the
preload of the heart. This allows the left ventricle to pump less blood during
systole, which means less work for the left ventricle.18 In the event when a
higher pulse pressure is necessary, such as patients with gastrointestinal
bleeding, the system uses a higher speed during systole and a lower speed
during diastole to create a larger pulse. The difference between systolic and
diastolic pump speeds is called ‘‘DRPM.’’
Signal Processing
The pulsatile algorithm in our controller needs to swiftly modulate the
pump speed to be able to gate it with an electrocardiography (ECG) signal
for co-pulsation, counterpulsation, or fixed operation modes. Thus, the
response time of the system is of a unique interest to us, because heart rates
up to 120 beats/min with 30% systolic duration would limit us with a
window of 0.15 second for the period of systole. We have used amplifiers
and signal processing and filtering methods to further analyze an ECG
signal.
Communication
Many medically implanted devices use wired or wireless methods to
communicate with their external circuitry. Furthermore, we have inte-
grated an antenna, a transceiver unit (transmitter and receiver), and a
wireless network algorithm to enable our UMC-Physio to establish a reli-
able telemetry communication with an extracorporeal platform, such as a
smart phone, tablet, or personal computer. In our wireless networking,
the amplitude and width of the data pulses are kept constant in the sys-
tem. The position of each pulse is varied by instantaneous sampled value
of the modulating wave. This method is called ‘‘pulse position modula-
tion.’’ Our controller puts out a stream of pulses called ‘‘sync pulses,’’
which the external receiver recognizes with a circuitry called ‘‘phase
locked loop.’’ To create synchronization, an oscillator in the phase locked
loop generates pulses at the same frequency as the controller.
Backup and Safety
Because the system will be powered by using our FREE-D emitted
electromagnetic fields, we had to consider the noise potential might influ-
ence the proper function of our electronic implant. To significantly reduce
the EMF susceptibility of our controller, we have combined multiple
filtering mechanisms, ground isolation, and ground decoupling in our
design. Backup motor driver, overvoltage, and overcurrent protection cir-
cuits, thermal shutdown circuit, and independent pulse width modulation
generator are among other safety issues that we have incorporated in our
design. In addition, a suction event detection algorithm also was incorpo-
rated in the system for additional safety by detecting power consumption
peaks that are abnormal.
Design and Development
The schematic of our system was laid out on a compact 4-layer printed
circuit board using Altium Designer software (Altium, Australia) to run a
rotary blood pump with required safety and backup measures. The control
algorithms and graphical user interface were further developed in IAR Sys-
tem and LabVIEW software (both National Instruments, Austin, Tex)
respectively. The final system was coupled with our alternating current
to direct current converter and a receiver coil to wirelessly receive power
(Figure 1, A).rdiovascular Surgery c Volume 147, Number 1 193
FIGURE 1. A, The developed UMC-Physio coupled with the FREE-D receiver coil to wirelessly obtain power and run an LVAD pump. B, The external
graphical user interface embedded in a smartphone. This platform displays and controls an LVAD pump by wireless communication or Internet access.
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The UMC-Physio initially was tested in a mock circulation loop (MCL)
with the HeartMate II (Thoratec Co, Pleasanton, Calif) and HeartWare
Ventricular Assist Device (HeartWare Inc, Framingham, Mass) pumps
(Figure 2). For the continuous mode, the UMC-Physio ran the HeartMate
II axial pump for 2 weeks. The pump speed was gradually increased
from 6000 up to 13,000 revolutions per minute (rpms) to ensure
functionality. Next, the UMC-Physio drove the centrifugal pump for a
2-week period. The speed of the LVAD was changed from 1800 to
4000 rpms by 100 rpm steps.
For the pulsatile mode, we tested both axial and centrifugal pumps in the
MCL. The fraction of systole was gradually increased from 20% to 80%,
and the mean LVAD flow, produced by our controller, was measured at
various heart rates. In the second test, systolic, diastolic, mean aortic, and
pulse pressure were measured. Last, we investigated how our UMC-Physio
automatically increases the mean LVAD flow with increase in heart rates
of 40 to 120 beats/min. These were then verified by changes in DRPMs.FIGURE 2. Invitro test setupwhereanLVADpumpisplaced in anMCL.Thepres
HVAD, HeartWare Ventricular Assist Device; LVAD, left ventricular assist device
194 The Journal of Thoracic and Cardiovascular SurgMoreover, the pump’s outlet flow was estimated by recording the changes
in power consumption and speed of the controlled LVAD in the MCL. The
estimated flow was compared by the actual flow measured by the Transonic
Flow Sensor (Transonic System Inc, Ithaca, NY) to ensure its accuracy.
In Vivo Experiments
The protocol was approved by the Institutional Animal Care and Use
Committee and complied with the ‘‘Guide for the Care and Use of
Laboratory Animals.’’ For the in vivo testing, the combination of our
physiologic controller and HeartWare Ventricular Assist Device pumps
was implanted in 2 large female pigs. We performed proof of concept
in vivo experiments to investigate the feasibility and implantablility of
our controller, to study its interference with biological tissue and
temperature increase, to examine the effect of tissue impedance on our
telemetry communication, and to prove our system capability of
introducing pulsatile flow in the animals. The experiments were performed
without any manipulation in the animal’s vasomotor system (during thesure andflowaremeasuredby thecorresponding sensors.HMII,HeartMate II;
.
ery c January 2014
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manipulated with inotropic infusions and were kept in steady state before
initiating pulsatile mode).
The surgical approach briefly consisted of induction by intravenously
administered anesthesia. The animals were then intubated and ventilated.
The animals were maintained on isoflurane anesthesia throughout the
surgery. External ECG was set up via needle electrodes in the extremities.
A dwell-time silicone catheter was placed in the right internal carotid and
external jugular vein for pressure monitoring. A 16g catheter was placed
in the left external jugular vein for fluid maintenance and monitoring of
the central pressure in the heart. In addition to the central line, an intra-
venous catheter was placed in the cephalic or saphenous veins. Once the
animals were instrumented, systolic and diastolic pressure, central venous
pressure, heart rate, rectal temperature, oxygen saturation, and end-tidal
carbon dioxide were monitored continuously and whole blood sample
was collected for immediate hematocrit, coagulation profile, and blood
gases for regular assessment.
The chest of the animal was opened via a left lateral thoracotomy at the
fifth/sixth intercostal space, and the small portion of the fifth rib was
removed at the costochondral junction. Surgery was performed without
the use of cardiopulmonary bypass. The descending aorta was exposed,
and the azygous vein was separated.
A dose of heparin was administered to obtain an activated clotting time
greater than 400 seconds in preparation for anastomosis of the outflow graft
to the descending thoracic aorta. The graft was placed transdiaphragmati-
cally, positioned dorsally to prevent atelectasis of the lung, and
anastomosed end-to-side to the aorta. Antiarrhythmics were administered
in preparation for insertion of the inlet of the pump into the left ventricle
of the heart. Teflon pledgeted sutures were placed radially around the left
ventricular apex, and a 10- to 12-mm core of the apex was removed using
a circular trocar. The HeartWare Ventricular Assist Device inlet cannula
was placed in the ventricle. The inlet of the pump was secured by suturing
of the cannula sewing-ring to the apical pledgets.
The animal experiment was designed to test for the following
parameters: bio-interference, thermal changes, tissue impedance,
telemetry communication, continuous mode operation, and pulsatile
mode operation.
Statistical Analyses
The correlation among the variables (pump flow, heart rate, diastolic
pressure, systolic pressure, and pulse pressure) was tested by Pearson
correlation for all observations, in which a 2-tailed P value less than
.05 shows the existence of statistically significant correlation between
2 variables. Furthermore, Pearson correlation measures the strength and
direction of the linear relationship between the 2 variables. The correlation
coefficient can range from1 toþ1, with1 indicating a perfect negative
correlation, þ1 indicating a perfect positive correlation, and 0 indicating
no correlation at all. In addition, linear, logarithmic, and cubic regressions
were used where appropriate for examining relations between correlated
variables.
RESULTS
In Vitro
The UMC-Physio tolerated dynamic power fluctuations
introduced by wireless power delivery. During each 2-week
in vitro testing with axial and centrifugal pumps, there was
no telemetry disconnection, thermal shutdown event, sudden
speed changes, power dropout, or pump failure. Moreover,
the graphical user interface embedded in an iPhone
(Microsoft Corp, Redmond, Wash), iPad (Microsoft Corp),
and laptop enabled us to wirelessly observe the recorded
data and modify the LVAD configuration (Figure 1, B).The Journal of Thoracic and CaResponse to Physiologic Demands
When used with ECG gating, the UMC-Physio allowed
on-demand customization of operation with instantaneous
flow and rpm changes, resulting in a pulsatile flow
with adjustable pulse pressure. The controller responds to
increases and decreases in heart rate and automatically
adjusts pump flow and pulsatility accordingly.Axial Left Ventricular Assist Device (HeartMate II)
Figure 3, A, demonstrates that our controller increases the
mean flow of an axial pump by an average of 0.313 L/min
per 10 beats/min change in heart rate. Likewise, 1000
DRPM increases the mean flow in this pump by an average
of 0.24 L/min. The linear regression equation with R2 of
0.981 is used; therefore, approximately 98% of the mean
pump flow (L/min) is explained by heart rate and DRPM.
This model is expressed as follows:
Mean LVAD Flow (L/min) ¼ 0.031333 $ Heart Rate
(beats/min) þ 0.00024089 $ DRPM (rpms) þ 2.38056.
Figure 3, B, shows that a 10% increase in fraction of
systole leads to an increase of 0.29 L/min more mean
flow in our system. The R2 for this linear model is 0.975.
The relationship (linear regression) is expressed as follows:
Mean LVAD Flow (L/min) ¼ 0.02486 $ Heart Rate
(beats/min) þ 0.02934 $ Fraction of Systole (%)þ 1.8883.
Figure 3, C to F, show the UMC-Physio increases the
systolic and diastolic pressures by increased in the heart
rate. The linear regression is expressed as follows:
Systolic Pressure (mm Hg) ¼ 0.44014 $ Heart Rate
(beats/min) þ 0.01041 $ DRPM (rpms) þ 2.02963 and
Diastolic Pressure (mm Hg) ¼ 0.41806 $ Heart Rate
(beats/min) þ 0.00042593 $ DRPM (rpms) þ 4.85185.
Figure 3, G, shows that increase in DRPM creates more
pulse pressure. Figure 3, H, proves that our controller
consumes less power compared with the HeartMate II
controller to achieve the flow and speeds for the HeartMate
II pump, being more efficient by a mean of 17.54%. The
relation between efficiency and flow (independent variable)
is estimated by curve approximation. As a result, the cubic
model has been used because of its highest R2 (0.999). The
efficiency is estimated by the following:
Efficiency (%) ¼ 0.08309 $ Flow3 þ 1.897 $ Flow2 þ
13.907 $ Flow (L/min)  15.6778.Centrifugal Left Ventricular Assist Device
(HeartWare Inc)
Figure 4, A, reveals that our controller can increase
the mean flow of a centrifugal pump by 0.22 L/min when
the heart rate increases by 10 beats/min. Likewise, 500
DRPM increases the mean flow in this pump by an
average of 0.319 L/min. The linear regression was used
because of an R2 value of 0.885. Thus, approximately
88% of the data in the LVAD mean flow are explained byrdiovascular Surgery c Volume 147, Number 1 195
FIGURE 3. The result of our in vitro testing with the HeartMate II (Thoratec Co, Pleasanton, Calif) pump. Most of these equations are related to a
specific MCL. A, Our controller adapts to changes in heart rate to create the corresponding mean LVAD flow. The degree of pulsatility also changes the
mean flow. The linear regression for this model is as follows: Mean LVAD Flow (L/min) ¼ 0.031333 $ Heart Rate (beats/min) þ 0.00024089 $ DRPM
(rpms) þ 2.38056. B, A 10% increase in fraction of systole increases the mean flow in our system by 0.29 L/min; therefore, more flexibility is added to
adapt to the patient’s everyday life. This relationship is modeled as follows: Mean LVAD Flow (L/min) ¼ 0.02486 $ Heart Rate (beats/min) þ 0.02934
$ Fraction of Systole (%) þ 1.8883. C to F, The UMC-Physio changes the systolic and diastolic pressures by increases or decreases in the heart rate.
The following equations represent the estimated systolic and diastolic pressures: Systolic Pressure (mm Hg) ¼ 0.44014 $ Heart Rate (beats/min) þ
0.01041 $ DRPM (rpms) þ 2.02963 Diastolic Pressure (mm Hg) ¼ 0.41806 $ Heart Rate (beats/min) þ 0.00042593 $ DRPM (rpms) þ 4.85185.
G, Increments inDRPMgeneratemore pulsatility. H, For 2 watts of power, the UMC-Physio produces 5.5 L/min of flow, whereas the HeartMate II controller
can create only 3.8 L/min; therefore, our controller is on average more efficient by 17.54%. This result is good evidence for how pump controller
optimization and precise control can contribute to the efficiency of an LVAD. The efficiency is estimated by the following: Efficiency (%) ¼ 0.08309 $
Flow3 þ 1.897 $ Flow2 þ 13.907 $ Flow (L/min)  15.6778. bmp, Beats/min; LVAD, left ventricular assist device; DRPM, difference between systolic
and diastolic pump speeds; UMC-Physio, ultra-compact implantable physiologic controller.
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Dheart rate andDRPM. The regression model for this graph is
as follows:
Mean LVAD Flow (L/min) ¼ 0.0226 $ Heart Rate
(beats/min) þ 0.000638222 $ DRPM (rpms) þ 3.7245.
Figure 4, B, confirms that an increase in fraction of sys-
tole increases the mean by 0.2 L/min. The R2 for this
linear regression is 0.998; thus, approximately 99.8% of196 The Journal of Thoracic and Cardiovascular Surgthe data in LVAD mean flow are explained by heart rate
and fraction of systole. The regression equation seems
to be useful for making predictions because the value of
R2 is close to 1. This formula explains this linear
regression:
Mean LVAD Flow (L/min)¼ 0.0046 $ Heart Rate (beats/
min) þ 0.0205 $ Fraction of Systole (%) þ 4.09312.ery c January 2014
FIGURE 4. The results of the in vitro testing with the HeartWare Ventricular Assist Device (HeartWare Inc, Framingham, Mass) pump. The results are
related to our MCL. A, The UMC-Physio increases the mean flow of the centrifugal pump by 0.22 L/min with 10 beats/min in the heart rate. The linear
regression model for this graph is Mean LVAD Flow (L/min) ¼ 0.0226 $ Heart Rate (beats/min) þ 0.000638222 $ DRPM (rpms) þ 3.7245. B, Confirms
that 10% increase in fraction of systole linearly increases the mean LVAD flow by 0.2 L/min. This formula explains this linear regression: Mean LVAD Flow
(L/min) ¼ 0.0046 $ Heart Rate (beats/min) þ 0.0205 $ Fraction of Systole (%) þ 4.09312. C to F, Heart rates up to 80 beats/min will increase the systolic
and diastolic pressures produced by our controller. The systolic and diastolic pressures can be estimated by the following formulas: Systolic Pressure
(mm Hg) ¼ 0.50067 $ Heart Rate (beats/min) þ 0.02364 $ DRPM (rpms) þ 31.9855 Diastolic Pressure (mm Hg) ¼ 0.26817 $ Heart Rate
(beats/min)þ 0.00188 $DRPM (rpms)þ 32.085. G, Pulse pressure can be easily controlled by our system; the linear regression is modeled as Pulse Pressure
(mm Hg) ¼ 0.2325 $ Heart Rate (beats/min) þ 0.02176 $ DRPM (rpms)  0.14. H, Proves that our controller is also more efficient than the HeartWare
Ventricular Assist Device controller. The descriptive statistics indicate that our controller is more efficient by a mean of 35.49%. Efficiency is modeled
as follows: Efficiency (%) ¼ 2.648 $ Flow2  32.630 $ Flow (L/min) þ 132.964. bmp, Beats/min; LVAD, left ventricular assist device; DRPM, difference
between systolic and diastolic pump speeds; UMC-Physio, ultra-compact implantable physiologic controller.
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that will increase the systolic and diastolic pressures
produced by our controller and the LVAD. The systolic
and diastolic pressures can be estimated by the following
formulas:
Systolic Pressure (mm Hg) ¼ 0.50067 $ Heart Rate
(beats/min) þ 0.02364 $ DRPM (rpms) þ 31.98556 and
Diastolic Pressure (mm Hg) ¼ 0.26817 $ Heart Rate
(beats/min) þ 0.00188 $ DRPM (rpms) þ 32.08556.The Journal of Thoracic and CaFigure 4, G, shows that pulse pressure can be easily
controlled by our system. The linear regression is as
follows:
Pulse Pressure (mm Hg) ¼ 0.2325 $ Heart Rate (beats/
min) þ 0.02176 $ DRPM (rpms)  0.1.
Figure 4, H, shows that our controller is more efficient
that the HeartWare Ventricular Assist Device controller.
The relation between efficiency and flow (independent var-
iable) is estimated by cubic estimation because it has therdiovascular Surgery c Volume 147, Number 1 197
FIGURE 5. Representative demonstration of the power consumption and speed of a HeartWare Ventricular Assist Device pump in one of our in vivo
experiments. The consistent and smooth pump speed indicates how our control adapts to the sudden changes of our wireless power delivery. In addition,
it displays the EMF noise-free telemetry data. The temperature of the implanted unit also is graphed to illustrate therewas no temperature increase in the unit
that might affect the surrounding tissues. HVAD, HeartWare Ventricular Assist Device; RPM, revolutions per minute; UMC-Physio, ultra-compact
implantable physiologic controller.
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statistics indicate that our controller is more efficient by
mean of 35.49%. Efficiency is modeled as follows:
Efficiency (%)¼ 2.648 $Flow2 32.630 $Flow (L/min)þ
132.964 (these results are based on the specific MCL that we
used and can vary in a biological system).In Vivo
The controller successfully ran an untethered HeartWare
Ventricular Assist Device pump for 3 hours in each animal
with continuous and pulsatile modes (cumulatively 6 hours
of experimental data). We initially tested the ability of the
controller to run the pump in the continuous mode to
assess power consumption in comparison with HeartWare
Ventricular Assist Device controller. Then we tested
efficiency as a baseline measure of overall controller
performance. Our study showed that there was no biological
tissue interference, temperature increase, or network mis-
matching in our system. The tissue impedance decreased
our communication distances. Figure 5 also shows that198 The Journal of Thoracic and Cardiovascular Surgour controller automatically adapts to the dynamic changes
in the wireless power to create a steady pump speed.DISCUSSION
The human heart and circulation have developed over
millennia—starting from the primitive coelom that was a pas-
sive receptacle forgas exchange, feeding, and sexual reproduc-
tion lined by endoderm to subsequent lining of the coelomic
cavity by mesodermal contractile cells, which became a
‘‘gastrovascular organ.’’ Further differentiation into a peri-
staltic heart in Chordata and vertebrates leads to the sophisti-
cated differentiation from a primitive tubular hearts into a
looped, unidirectional circulation with a highly specialized
conductive and pacemaker cells. The subsequent parallel pul-
monary circulation was a further evolutionary step. The evi-
dence to suggest the primordial gastrovascular structure to
today’s highly specialized cardiac structure is demonstrable
by the common nerve supply to heart and gut by the central
nervous system and the pulsatility that has been the hallmark
of mammalian circulation for millennia.19ery c January 2014
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DRotary pumps use controllers that run an LVAD pump at a
constant speed.20 However, the continuous flow is
mostly acceptable for short-term use of an LVAD (eg, bridge
to transplant), but as we witness more widespread use and
long-term support such as destination therapy, several
unintended effects of continuous flow are becoming
apparent.8,9,12-15,21 After all, the continuous flow associated
with current LVAD devices was a result of replacing earlier
pulsatile devices with a more durable pumping system at the
cost of pulsed operation. Our technologic advance allows
leveraging both the durability of rotary pumps and restoring
the pulsed operation simultaneously.
Several researchers have tried to mimic nature by
designing physiologic LVAD controllers by using
proportional-integral22,23 and fuzzy logic24,25 control
algorithms to automatically modulate the constant speed
of the pump. However, our system combines adaptive
optimal proportional feedback control algorithm, ECG
gating, and head pressure and flow estimation to perform
its physiologic modulation during systole and diastole.
Previous studies26,27 produced acceptable results for the
estimation of the pulsatile flow and head pressure, but
they did not investigate the stability of the transient
response of the pump flow. The transient response has
been demonstrated.28-30 Moreover, the head pressure
estimation observed in other studies31 suffers from a time
delay because of the use of excessive filtering. Our system
uses a simple low-pass filter to estimate the transient and
steady-state head pressure and flow. This method produces
an instant result with no delay. Although the real-time
estimation process requires extra computation, it is a simple
way to substitute sensor implementation. All of our flow
and head pressure estimations were performed in our MCL.
Prior attempts include magnets, capacitive communica-
tion, Bluetooth, Wi-Fi, ultrasound, and other radio
frequencies to wirelessly communicate with an implantable
medical device. The capacitive intra-body communication
requires electrodes to be placed on or near the skin.
Of these, ultrasound and magnets have low transmission
efficiency and range through the biological tissue and are
challenging to miniaturize. Radiofrequencies, such as a
medical implant communication service band or Wireless
Medical Telemetry Service, require bulky antennas that
restrict how small the controller can be. We have used
industrial, scientific, and medical radio bands of 2.4 GHz
with a highly automated communication that has a short
wavelength and therefore a small size.
Data modulation has been accomplished by amplitude
shift key, phase shift keying, continuous phase modulation,
and other methods to translate data. Our pulse position
modulation method has the advantage of pulses with
constant amplitude and width, but the disadvantage of
requiring synchronization between transmitter and receiver.
The obtained telemetric data during our experiments wereThe Journal of Thoracic and Canoise-free from sources such as the EMF and pulse width
modulation switching. Our graphical user interface enables
a physician to monitor and control the patient’s LVAD even
when not in wireless range of the implanted device by using
the Internet to access the patient’s external receiver that in
turn relays the information to and from the implanted
controller. The corresponding data can be placed in the
database for future review and analysis.
The UMC-Physio rapidly synchronizes the pump to the
heart rate to mimic physiologic flow to adapt to the patient’s
everyday physiologic demands. Our controller can
produce the same pump speed and flow rate at a lower
power than the HeartWare Ventricular Assist Device and
HeartMate II controllers, making it more efficient. The
power consumption of the controller is extremely low
because of the accurate commutation and sleep mode.
The UMC-Physio enables an LVAD to be controlled
digitally, bringing precise control, higher efficiency, and
faster response time for this type of pump. The UMC-
Physio can control both axial and centrifugal blood pumps.
Future Research and Study Limitations
The scope of the current article is limited to proving the
feasibility of the bench-top testing of such a system in a
physiologic MCL and initial in vivo proof of concept. In
our future research, we will study the performance of the
controller in heart failure models in an acute and chronic
setting. In these studies, we will test how our technology
creates pulsatile flow that is responsive to physiologic
demand in the complex milieu of a neurologic, baroreflex,
and hormonal changes. Theoretic conditions that may
have bearing on the clinical application will include
extremes of physiologic states, such as extreme hyperten-
sion, severe hypotension, severe bradycardia, and
tachyarrhythmias. However, these conditions are usually
controlled in the population with LVADs by pharmacologic
means and use of appropriate pacing and tachyarrhythmia
therapies; thus, they should not pose problems for the
workings of the UMC-Physio controller.
CONCLUSIONS
The novel combination of wireless powering, a
user-friendly interface, and a small footprint makes this
an ideal totally implantable LVAD system. We have
demonstrated the feasibility of a controller that can
create versatile physiologic flow with a conventional
continuous-flow pump.
The authors thank Elsa Su, BS (Statistics), and Samira
Ghadyani, MBA, for statistical assistance.
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Dr Vivek Rao (Toronto, Canada). You mentioned at the outset
that this is a physiologic controller system, but it seems to me you
are still setting your speed and algorithms for inducing pulse. Does
your controller allow you to modify it on the basis of the native
heart rate? If your patient is exercising and the native heart rate in-
creases, will this controller automatically change your ventricular
assist device setting?
Dr Asgari. Yes, the system is synchronized with ECG that is
measured from ECG sensors, so the LVAD will respond to
increases in heart rate associated with day-to-day physiologic
stresses, such as exercise, climbing stairs, or Valsalva maneuver.
The decreases in heart rate associated with diurnal variation
(eg, sleeping or resting) will be detected, and the LVAD will
respond accordingly. One can define different percentages of
systole and diastole and automatically vary their duration on
the basis of the heart rate. The controller can run the LVAD in a
co-pulsation, counterpulsation, or fixed mode of operation.
This way, it is truly a pump that responds to physiologic demands.ery c January 2014
APPENDIX: DESIGNOFA LEFT VENTRICULAR
ASSIST DEVICE
The stationary part in a typical rotary LVAD is the
electromagnet, called the ‘‘stator.’’ The rotating part
contains a permanent magnet, called the ‘‘rotor.’’
Permanent magnets are made of magnetic materials, such
as neodymium, iron, and boron. Each magnet has 2 poles:
North and South. The North pole of a magnet is the pole
that, when the magnet is freely suspended, points toward
the Earth’s North magnetic pole in the Arctic. An
electromagnet is made from a coil of wire that acts as a
magnet when an electric current passes through it, but stops
being a magnet when the current stops. The coil often is
wrapped around a core of ‘‘soft’’ ferromagnetic material,
such as steel, which greatly enhances the magnetic field
produced by the coil. By changing the direction of the
current that goes through the electromagnet, the magnetic
poles will change.
When 2 magnets are brought close to each other, similar
poles repel each other and opposite poles attract. For
example, in Appendix Figure 1, A, the stator’s electromag-
nets are magnetized. Therefore, the opposite poles of the
electromagnets and permanent magnets attract each other.
In Appendix Figure 1, B, the direction of the current in the
coils is reversed, and therefore opposite poles are formed.
Now the rotor’s poles are repelled by the electromagnet’s
poles and a rotational movement is generated. In Appendix
Figure 1, C, the opposite poles are aligned again. With this
method, one can easily control the rotation of a rotor.
Current rotary blood pumps are made of a 3-phase
brushless direct current motor, that is, they have 3 sets of
electromagnetic coils. Some LVADs (eg, the HeartMate
II, Thoratec Co, Pleasanton, Calif) have impellers made
of permanent magnets with 2 poles, whereas some have
4 poles (eg, the HeartWare Ventricular Assist Device,
HeartWare Inc, Framingham, Mass). Appendix Figure 1,
D, displays a 3-phase brushless direct current motor with
2-pole permanent magnets. The repulsion and attraction
forces of the stator poles and rotor poles will generate the
rotational movement needed to propel the blood.
Appendix Figure 1, E, shows a simplified illustration of
brushless direct current motor construction. To control the
movement of the impeller, we can use 6 switches to control
the direction of the currents that go through electromagnets
and therefore choose when an electromagnet is a north or
south pole.
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APPENDIX FIGURE 1. A-C, The step by step movement of a rotor in a simple 2-phase brushless motor. When current passes through the electromagnets
(wire winding around an iron core), they will be magnetized and their poles will attract the opposite poles of the permanent magnet (rotor). Once the
direction of the current is reversed, the poles of the electromagnets will be reversed and, therefore, like poles of the electromagnet and rotor will be aligned.
This would create a force that causes the rotor to move. The rotor moves until its poles are facing the opposite poles of the electromagnet. By alternating the
direction of the current, we can therefore rotate the rotor. D, A simplified version of a 3-phase brushless direct current motor that is a basis of a left ventricular
assist device. E, The schematic of the electronic switches that control the direction of the current that passes through the electromagnets of a left ventricular
assist device. The schematic view of how electromagnets are wound is shown on the right side.
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